ACU Surges on Strong Q2 2026 Earnings Driven by MyMedic Acquisition

• Acme United (ACU) reported a 50.62% earnings per share beat, posting diluted EPS of $1.22 against consensus estimates of $0.81 for the second quarter of 2026.
• Revenue reached $62.7 million, surpassing forecasts of $58.1 million, while shares surged nearly 18% to approach their 52-week high of $51.88.
• The earnings beat was primarily fueled by the acquisition of MyMedic, which contributed to a 16% year-over-year sales increase and expanded gross margins to 42.6%.
• Management anticipates continued margin recovery as the company transitions from higher-tariff inventory to lower-cost stock, though elevated SG&A expenses remain a key risk.

Acme United Corporation (ACU) delivered a robust performance in the second quarter of 2026, significantly outperforming Wall Street expectations across both earnings and revenue metrics. The company reported diluted earnings per share (EPS) of $1.22, representing a substantial 50.62% positive surprise compared to the consensus estimate of $0.81 . This strong financial result was mirrored in the top line, where revenue hit $62.7 million, beating the forecasted $58.1 million by nearly 8% . Following the release of these results, the market reacted decisively, with ACU shares surging approximately 17.5% to trade near their 52-week high of $51.88 . The positive market reception underscores investor confidence in the company's ability to leverage recent strategic acquisitions for tangible financial growth.

The primary driver behind this impressive quarter was the acquisition of MyMedic, a move that has fundamentally shifted the company's revenue trajectory. Year-over-year sales growth reached 16.15%, a figure heavily influenced by the integration of MyMedic into Acme United's existing portfolio . Even when excluding the impact of the acquisition, the company demonstrated strong underlying momentum with 8% organic growth . This dual engine of acquisition-driven expansion and organic improvement has allowed Acme United to significantly expand its gross margins to 42.6%, up from 41.0% in the prior year period . The margin expansion indicates improved pricing power and operational efficiencies, providing a solid foundation for future profitability.

How Is MyMedic Changing Acme United’s Distribution Strategy?

MyMedic is not merely a revenue contributor but a strategic pivot point for Acme United’s long-term distribution model. CEO Johnsen highlighted ongoing integration efforts aimed at expanding MyMedic’s distribution beyond its current direct-to-consumer channels into mass retail markets . This strategic expansion is expected to drive strong profitability in the fourth quarter due to seasonal demand, leveraging Acme United’s established industrial and consumer networks . The move into mass retail represents a significant scaling opportunity for MyMedic, allowing it to reach a broader customer base and increase brand visibility.

Management is actively focusing on optimizing this integration to ensure that the high growth rates observed in Q2 are sustainable. The company expects the mass retail expansion to complement its existing direct-to-consumer success, creating a diversified revenue stream that is less dependent on single channels . By leveraging its distribution expertise, Acme United aims to accelerate MyMedic’s market penetration and capture a larger share of the medical products sector. This strategic shift is expected to enhance the company's overall market position and provide a more resilient revenue base.

What Are the Key Risks and Financial Headwinds?

Despite the strong earnings beat, investors must remain cognizant of several financial headwinds and operational risks. Selling, General, and Administrative (SG&A) expenses remain elevated at 32% of sales, which could pressure net margins if not managed effectively . Additionally, the company faces potential volatility from fluctuating tariff and freight costs, as well as currency risks that could impact international revenue streams . The Canadian market, in particular, has lagged behind other regions, highlighting uneven geographic performance that management is working to address . These factors suggest that while the immediate outlook is positive, ongoing execution and cost control will be critical for sustaining growth.

Insider activity provides additional context to the company's financial health and market sentiment. COO Brian S. Olschan recently exercised stock options for 20,000 shares, realizing a transaction value of approximately $841,099, signaling executive confidence in the company's trajectory . However, other insiders have reduced their stakes, with total insider sales amounting to 23,247 shares over the last 90 days, representing roughly $1.26 million in value . Despite this selling pressure, insiders still hold a significant 29.50% ownership stake, indicating continued alignment with shareholder interests . The company maintains a prudent balance sheet with a low debt-to-equity ratio of 0.30 and a current ratio of 4.41, providing financial flexibility to navigate these challenges . Acme United also recently increased its quarterly dividend to $0.16, resulting in an annualized yield of approximately 1.0%, with a sustainable payout ratio of 26.89% . This conservative capital allocation strategy further underscores the company's commitment to shareholder returns while managing growth investments.